|
|||||
|
|
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials |
|
| Authors: | Sebastian P. Mondaca MD Dazhi Liu PharmD BCOP Jessica R. Flynn Sandy Badson Stefan Hamaway BS Mrinal M. Gounder MD Danny N. Khalil MD PhD Alexander E. Drilon MD Bob T. Li MD MPH Komal L. Jhaveri MD Alison M. Schram MD Katherine E. Kargus RN Mary Kate Kasler DNP MSN Natalie M. Blauvelt Neil H. Segal MD PhD Marinela Capanu PhD Margaret K. Callahan MD PhD David M. Hyman MD Maya Gambarin-Gelwan MD James J. Harding MD |
| Affiliation: | 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;2. Department of Pharmacy Service, Memorial Sloan Kettering Cancer Center, New York, New York;3. Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York;4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York;5. Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, New York |
| Abstract: | |
| Keywords: | advanced solid tumors drug-induced liver injury immunotherapy phase 1 precision medicine |